View our Blog

Wellnex Life Limited Shortfall Placement

Wellnex Life Limited - Shortfall Placement

Offer Details

This Offer is now Closed

TBA

*Offer is at the same price as the institutional placement

Offer Details

30-Day VWAP*

$0.71

Offer Price

$0.65

*This offer represents a 8.6% discount to the volume weighted average price during the 30 trading days before the Entitlement Offer was announced on the 10th February 2025.  Wholesale investors have the opportunity to participate in the shortfall placement.

“After spending years building a portfolio of brands and licensing deals – including with one of the largest consumer health companies in the world – we are finally seeing the traction we’ve been looking for, as evidenced by our recent doubling of revenues and margins. I see Wellnex at an inflection point now and have never been more excited about the future of the company.”
Zack Bozinovski – Managing Director

Request An Allocation

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets Pty Ltd provide Corporate Advisory Services to Wellnex Life Limited and will receive fees for its role in managing this offer based on the uptake by investors.

Overview

Wellnex Life Limited (ASX:WNX) is a consumer healthcare business with a proven capability of turning consumer trends into marketable products and getting those onto shelves fast via a market-leading distribution network.

Company Highlights:

  • Portfolio of five 100% owned brands – such as Pain Away, Australia’s second largest topical pain relief brand.
  • Game-changing partnership with Haleon – one of the largest consumer health businesses in the world (Sensodyne, Voltaren, Panadol) – with first UK order received in H1 FY25.
  • Recently received $14.3m investor commitments to unlock a dual listing in the UK which will recapitalise the business and set it up for fast, debt-free growth.

Wellnex recently saw a doubling of revenues and margins in H1 FY25, including over $3m sales per month in both November and December.

Its board features some of Australia’s leading consumer health veterans, including successful entrepreneurs, blue chip executives and a former director of the Pharmacy Guild of Australia.

Parallel to this rights issue, Wellnex is conducting an IPO on AIM (part of the London Stock Exchange) to boost investor interest via a dual listing in Europe.

Close

Speak to An Advisor

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets are the advisors assisting with the management of this offer and may receive fees depending on whether an offer is taken up by investors.

Request An Allocation

Shortfall Placement Offer Details

30-Day VWAP*

$0.71

Offer Price

$0.65

*This offer represents a 8.6% discount to the volume weighted average price during the 30 trading days before the Entitlement Offer was announced on the 10th February 2025.  Wholesale investors have the opportunity to participate in the shortfall placement.

Request An Allocation

Company Presentation

Watch the Q&A update here , watch the latest shareholder briefing recording here or read the company presentation here

Investor Briefing

Zack gives an update on Wellnex’ progress including its game-changing deal with Haleon and recent doubling of revenues and margins.
42 mins | 21 February, 2025
Watch video

Q&A Update

Zack discusses WNX’ recent progress, including their financial traction, UK IPO and international partnerships with $60bn health giant Haleon.
13 mins | 20 February, 2025
Watch video

Company Presentation Deck

 
26 pages | February, 2025
Read PDF

Investment Highlights

  • Placement of the shortfall of Wellnex’s 1-for-1 traditional pro-rata non-renounceable entitlement offer (Entitlement Offer) to raise approximately $22.1 million.
  • The placement offer price is A$0.65 per share.
  • Represents discounts of:
    • 8.6% to the 30-day VWAP price of A$0.71*

*as of offer launch on 10th February 2025.

Request an allocation

Shortfall Placement Offer Details

30-Day VWAP*

$0.71

Offer Price

$0.65

*This offer represents a 8.6% discount to the volume weighted average price during the 30 trading days before the Entitlement Offer was announced on the 10th February 2025.  Wholesale investors have the opportunity to participate in the shortfall placement.

Request An Allocation

Board

George Tambassis

Non-executive Chair

Mr Tambassis is a pharmacist with over 35 years of operational experience in Community Pharmacies, and was a Non-Executive Director of ASX listed pharmaceutical wholesaler and franchisor Australian Pharmaceutical Industries (API), a Non-Executive Director at Kings Transport Consolidated Group Pty Ltd, and Chair of the Advisory Board at the Australian Biologics Academy – part of the Arrotex Pharmaceuticals group of companies.

Zack Bozinovski

Managing Director

Zack is a highly successful and seasoned executive in the Australian retail industry with over 35 years’ experience within FMCG and Pharmaceutical companies in Australia and internationally. Zack has previously held senior positions at Uncle Tobys/Goodman Fielder, PepsiCo and Sigma and successfully developed and established many brands in the Australian retail sector. Zack most recently held the position of Managing Director at Brands Solutions Australia. Zack was also a co-founder of Voost Vitamins, recently sold to Proctor & Gamble.

George Karafotias

Chief Executive Officer

George is a specialist in restructuring, reinventing and implementing turnaround strategies for various ASX-listed companies with great success. His extensive experience includes an established track record with publicly-traded businesses, predominantly in senior executive positions. He is also a non-executive Director of Perpetual Resources Limited (ASX:PEC), and holds a Bachelor of Commerce degree from the University of Adelaide.

Andrew Vidler

Independent Non-Executive Director

Andrew Vidler has comprehensive experience across retail, consumer health products and retail pharmacy. Andrew in his over 30 years’ experience includes nearly 20 years with the EBOS Group (formerly FH Faulding, Mayne Group and Symbion), where across many roles he led the Terry White and Chemmart pharmacy brands and the Endeavour consumer health products business. For the last 4 years Andrew worked for API Limited (now Wesfarmers Health) where he was responsible for the Priceline retail and Priceline pharmacy business. Andrew has an excellent track record of building strong team cultures while ensuring they say focused on the marketplace and building customers with an active preference for the products, brands and retailers he oversees.

Jeffrey Yeh

Non-Executive Director

Jeffrey Yeh is an experienced all-rounded entrepreneur, with over 21 years’ experience in all aspects of pharmaceutical sales, marketing, production, quality assurance, operations, logistics, finance and management. Jeffrey co-founded Homart Pharmaceuticals in 2002, and since then has grown Homart into a premier and award winning manufacturing and brand business with over 200 employees and an international presence.

Eric Jiang

Independent Non-Executive Director

Eric Jiang is a corporate adviser and independent board member. Eric brings a distinctive understanding of the cultural, economic and strategic context in which Australian businesses engage with China. Eric has previously sat on the boards of ASX listed corporates Connexion Media Limited (ASX:CXZ), Perpetual Resources Limited (ASX:PEC) and Wingara AG Limited (ASX:WNR). He is a past President of The Chinese Community Council of Australia.

George Tambassis

Non-executive Chair

Mr Tambassis is a pharmacist with over 35 years of operational experience in Community Pharmacies, and was a Non-Executive Director of ASX listed pharmaceutical wholesaler and franchisor Australian Pharmaceutical Industries (API), a Non-Executive Director at Kings Transport Consolidated Group Pty Ltd, and Chair of the Advisory Board at the Australian Biologics Academy – part of the Arrotex Pharmaceuticals group of companies.

Zack Bozinovski

Managing Director

Zack is a highly successful and seasoned executive in the Australian retail industry with over 35 years’ experience within FMCG and Pharmaceutical companies in Australia and internationally. Zack has previously held senior positions at Uncle Tobys/Goodman Fielder, PepsiCo and Sigma and successfully developed and established many brands in the Australian retail sector. Zack most recently held the position of Managing Director at Brands Solutions Australia. Zack was also a co-founder of Voost Vitamins, recently sold to Proctor & Gamble.

George Karafotias

Chief Executive Officer

George is a specialist in restructuring, reinventing and implementing turnaround strategies for various ASX-listed companies with great success. His extensive experience includes an established track record with publicly-traded businesses, predominantly in senior executive positions. He is also a non-executive Director of Perpetual Resources Limited (ASX:PEC), and holds a Bachelor of Commerce degree from the University of Adelaide.

Andrew Vidler

Independent Non-Executive Director

Andrew Vidler has comprehensive experience across retail, consumer health products and retail pharmacy. Andrew in his over 30 years’ experience includes nearly 20 years with the EBOS Group (formerly FH Faulding, Mayne Group and Symbion), where across many roles he led the Terry White and Chemmart pharmacy brands and the Endeavour consumer health products business. For the last 4 years Andrew worked for API Limited (now Wesfarmers Health) where he was responsible for the Priceline retail and Priceline pharmacy business. Andrew has an excellent track record of building strong team cultures while ensuring they say focused on the marketplace and building customers with an active preference for the products, brands and retailers he oversees.

Jeffrey Yeh

Non-Executive Director

Jeffrey Yeh is an experienced all-rounded entrepreneur, with over 21 years’ experience in all aspects of pharmaceutical sales, marketing, production, quality assurance, operations, logistics, finance and management. Jeffrey co-founded Homart Pharmaceuticals in 2002, and since then has grown Homart into a premier and award winning manufacturing and brand business with over 200 employees and an international presence.

Eric Jiang

Independent Non-Executive Director

Eric Jiang is a corporate adviser and independent board member. Eric brings a distinctive understanding of the cultural, economic and strategic context in which Australian businesses engage with China. Eric has previously sat on the boards of ASX listed corporates Connexion Media Limited (ASX:CXZ), Perpetual Resources Limited (ASX:PEC) and Wingara AG Limited (ASX:WNR). He is a past President of The Chinese Community Council of Australia.

Management

George Karafotias

Chief Executive Officer

George is a specialist in restructuring, reinventing and implementing turnaround strategies for various ASX-listed companies with great success. His extensive experience includes an established track record with publicly-traded businesses, predominantly in senior executive positions. He is also a non-executive Director of Perpetual Resources Limited (ASX:PEC), and holds a Bachelor of Commerce degree from the University of Adelaide.

Jeffrey Yeh

Non-Executive Director

Jeffrey Yeh is an experienced all-rounded entrepreneur, with over 21 years’ experience in all aspects of pharmaceutical sales, marketing, production, quality assurance, operations, logistics, finance and management. Jeffrey co-founded Homart Pharmaceuticals in 2002, and since then has grown Homart into a premier and award winning manufacturing and brand business with over 200 employees and an international presence.

George Karafotias

Chief Executive Officer

George is a specialist in restructuring, reinventing and implementing turnaround strategies for various ASX-listed companies with great success. His extensive experience includes an established track record with publicly-traded businesses, predominantly in senior executive positions. He is also a non-executive Director of Perpetual Resources Limited (ASX:PEC), and holds a Bachelor of Commerce degree from the University of Adelaide.

Jeffrey Yeh

Non-Executive Director

Jeffrey Yeh is an experienced all-rounded entrepreneur, with over 21 years’ experience in all aspects of pharmaceutical sales, marketing, production, quality assurance, operations, logistics, finance and management. Jeffrey co-founded Homart Pharmaceuticals in 2002, and since then has grown Homart into a premier and award winning manufacturing and brand business with over 200 employees and an international presence.

Latest News

The Australian

Wellnex directors commit to $1.5 million in entitlement offer ahead of London listing

February 21, 2025

The Australian

London calling: Wellnex Life secures $14.3 million for LSE listing

February 20, 2025

Small Caps

Wellnex Life expands global reach with UK market entry and new product approval

February 4, 2025

Request An Allocation

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets Pty Ltd provide Corporate Advisory Services to Wellnex Life Limited and will receive fees for its role in managing this offer based on the uptake by investors.

*Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.

  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status.  Please refer to the Corporations Act:  Specifically Section 708(08) and Section s761G(7)
Any advice provided by Reach Markets, including on its website and by its representatives, is general advice only and does not consider your personal objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. You need to also read any relevant offer documents to understand the features, risks and returns associated with the investment to make your own informed decision.
Please click here to read our full general advice warning.
If you are thinking about acquiring a financial product, you should consider our Reach Markets Financial Services Guide (FSG) including the Privacy Statement.
Past performance is not a reliable indicator of future performance.
Close
Search

Hit enter to search or ESC to close